Loading
Every dated change on the records linked to Metastatic hormone-sensitive prostate cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
mHSPC with ADT alone (ARANOTE)
Median rPFS 33.
Radiographic progression-free survival hazard ratio 1.
rPFS HR 0.
Transdermal oestradiol suppressed testosterone as well as a luteinising hormone-releasing hormone agonist with no difference in time to first cardiovascular event (hazard ratio 1.
OS HR 0.
A milestone in how this cancer is treated.
mHSPC (TITAN)
mHSPC (ARCHES)
Radiographic progression-free survival at 24 months 68.
rPFS HR 0.
Enzalutamide added to testosterone suppression improved overall survival compared with a standard non-steroidal antiandrogen.
A milestone in how this cancer is treated.